title: CCR5-Δ32 Heterozygosity, HIV-1 Reservoir Size, and Lymphocyte Activation in Individuals Receiving Long-term Suppressive Antiretroviral Therapy.
abstract: We conducted a case-controlled study of the associations of CCR5-Δ32 heterozygosity with human immunodeficiency virus type 1 (HIV-1) reservoir size, lymphocyte activation, and CCR5 expression in 114 CCR5(Δ32/WT) and 177 wild-type CCR5 AIDS Clinical Trials Group participants receiving suppressive antiretroviral therapy. Overall, no significant differences were found between groups for any of these parameters. However, higher levels of CCR5 expression correlated with lower amounts of cell-associated HIV-1 RNA. The relationship between CCR5-Δ32 heterozygosity, CCR5 expression, and markers of HIV-1 persistence is likely to be complex and may be influenced by factors such as the duration of ART.
authors.affiliation: Division of Infectious Diseases, Brigham and Women's Hospital Harvard Medical School.
authors.forename: Timothy J
authors.initials: TJ
authors.lastname: Henrich
authors.affiliation: Division of Infectious Diseases, Brigham and Women's Hospital.
authors.forename: Emily
authors.initials: E
authors.lastname: Hanhauser
authors.affiliation: Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston.
authors.forename: Linda J
authors.initials: LJ
authors.lastname: Harrison
authors.affiliation: Ragon Institute of MGH, MIT, and Harvard, Cambridge, Massachusetts.
authors.forename: Christine D
authors.initials: CD
authors.lastname: Palmer
authors.affiliation: Ragon Institute of MGH, MIT, and Harvard, Cambridge, Massachusetts.
authors.forename: Marisol
authors.initials: M
authors.lastname: Romero-Tejeda
authors.affiliation: Harvard Medical School Ragon Institute of MGH, MIT, and Harvard, Cambridge, Massachusetts.
authors.forename: Stephanie
authors.initials: S
authors.lastname: Jost
authors.affiliation: Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston.
authors.forename: Ronald J
authors.initials: RJ
authors.lastname: Bosch
authors.affiliation: Division of Infectious Diseases, Brigham and Women's Hospital Harvard Medical School.
authors.forename: Daniel R
authors.initials: DR
authors.lastname: Kuritzkes
mesh_terms: D019380:Anti-HIV Agents / Q000627:therapeutic use*; D016022:Case-Control Studies; D004270:DNA, Circular; D004279:DNA, Viral / Q000097:blood / Q000302:isolation & purification; D005260:Female; D020022:Genetic Predisposition to Disease; D015658:HIV Infections / Q000188:drug therapy* / Q000235:genetics*; D015497:HIV-1 / Q000235:genetics / Q000302:isolation & purification*; D006801:Humans; D008213:Lymphocyte Activation / Q000502:physiology*; D008297:Male; D012367:RNA, Viral / Q000097:blood / Q000302:isolation & purification; D019713:Receptors, CCR5 / Q000235:genetics / Q000378:metabolism*; D013601:T-Lymphocytes / Q000502:physiology
chemical_list: D019380:Anti-HIV Agents; C584933:CCR5 protein, human; D004270:DNA, Circular; D004279:DNA, Viral; D012367:RNA, Viral; D019713:Receptors, CCR5
keywords: CCR5-Δ32; HIV latency; HIV persistence; HIV reactivation; antiretroviral therapy; human immunodeficiency virus